TruAlt Bioenergy Utilizes Rs 519.63 Crore of IPO Proceeds in Q3FY26, Reports No Deviations
TruAlt Bioenergy Limited utilized Rs 519.63 crore of its Rs 750.00 crore IPO proceeds during Q3FY26, with monitoring agency Crisil Ratings confirming no deviations from stated objectives. The company deployed funds across capital expenditure (Rs 140.13 crore), working capital (Rs 263.22 crore), and general corporate purposes (Rs 69.99 crore), while maintaining Rs 230.37 crore in term deposits and bank accounts earning 5.00% returns.

*this image is generated using AI for illustrative purposes only.
TruAlt Bioenergy Limited has reported substantial progress in utilizing its Initial Public Offer (IPO) proceeds during the quarter ended December 31, 2025. The company utilized Rs 519.63 crore out of the total gross proceeds of Rs 750.00 crore, with monitoring agency Crisil Ratings Limited confirming no deviations from the stated objectives.
IPO Details and Financial Overview
The company's IPO was conducted from September 25, 2025, to September 29, 2025, raising gross proceeds of Rs 750.00 crore. After deducting issue expenses of Rs 92.96 crore, the net proceeds stood at Rs 657.04 crore.
| Financial Parameter | Amount (Rs crore) |
|---|---|
| Gross Proceeds | 750.00 |
| Issue Expenses | 92.96 |
| Net Proceeds | 657.04 |
| Total Utilized | 519.63 |
| Remaining Unutilized | 230.37 |
Utilization Across Key Objectives
The proceeds were allocated across three primary objectives as outlined in the offer document. The largest allocation was towards working capital requirements, followed by capital expenditure for multi-feedstock operations.
Capital Expenditure Progress
For funding capital expenditure towards setting up multi-feedstock operations at TBL Unit 4 of 300 KLPD capacity, the company utilized Rs 140.13 crore out of the allocated Rs 150.68 crore. The proceeds were used for purchasing plant and machinery to enable grain utilization as additional raw material in ethanol production.
Working Capital and Corporate Purposes
| Objective | Allocated Amount (Rs crore) | Utilized Amount (Rs crore) | Remaining (Rs crore) |
|---|---|---|---|
| Working Capital Requirements | 425.00 | 263.22 | 161.78 |
| General Corporate Purposes | 81.36 | 69.99 | 11.37 |
| Issue Expenses | 92.96 | 46.29 | 46.67 |
The working capital funds were deployed towards vendor payments, while general corporate purposes included meeting company expenses and investment in subsidiary Truault Gas Private Limited.
Deployment of Unutilized Proceeds
The remaining Rs 230.37 crore is strategically deployed across various financial instruments and accounts. The company has invested Rs 150.00 crore in term deposits with Kotak Mahindra Bank, earning returns of 5.00% with maturity on January 14, 2026.
| Investment Type | Amount (Rs crore) | Returns (%) | Market Value (Rs crore) |
|---|---|---|---|
| Term Deposits | 150.00 | 5.00 | 150.30 |
| Monitoring Account Balance | 47.54 | - | 47.54 |
| Public Offer Account Balance | 28.65 | - | 28.65 |
| Cash Credit Account Balance | 10.82 | - | 10.82 |
General Corporate Purpose Breakdown
The company provided detailed utilization of Rs 69.99 crore allocated for general corporate purposes, approved by the Board of Directors on February 3, 2026:
- Meeting company expenses: Rs 41.56 crore (including SBI cash credit adjustment and GST payments)
- Acquisition activities: Rs 8.43 crore for acquiring 51% shareholding in Truault Gas Private Limited
- Subsidiary investment: Rs 20.00 crore in Truault Gas Private Limited
Monitoring Agency Assessment
Crisil Ratings Limited confirmed that all utilization aligned with disclosures in the offer document. The monitoring agency reported no material deviations, unfavorable events affecting viability, or delays in implementation of stated objectives. The company maintained proper documentation through peer-reviewed independent chartered accountant certificates and management undertakings.
The monitoring report, reviewed and approved by the company's Audit Committee and Board of Directors on February 2, 2026, and February 3, 2026, respectively, demonstrates TruAlt Bioenergy's systematic approach to IPO proceeds deployment while maintaining regulatory compliance.

































